SCHEMBL97361

SCHEMBL97361

[CH2]c1ccc(NS(=O)(=O)c2ccc(NC(C)=O)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.68
MEN1 O00255 4/20 0.68
ALDH1A1 P00352 4/20 0.68
GAA P10253 3/20 0.68
GFER P55789 2/20 0.68
MAPK1 P28482 1/20 0.68
KDM1A O60341 1/20 0.67
KDM4E B2RXH2 1/20 0.67
CYP3A4 P08684 1/20 0.67
HPGD P15428 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
PKM P14618 2/20 0.64
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
MMP1 P03956 1/20 0.63
MMP2 P08253 1/20 0.63
MMP9 P14780 1/20 0.63
MMP8 P22894 1/20 0.63
MMP13 P45452 1/20 0.63
LMNA P02545 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402411 0.85 MEN1 (0.91) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL9365750 0.85 PKM (0.73) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL29118884 0.84 PKM (0.73) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL5318082 0.84 HPGD (0.74) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL11700730 0.83 MEN1 (0.82) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL29364930 0.83 POLB (0.80) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL5037216 0.83 KDM1A (0.69) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL95420 0.82 SMN1; SMN2 (0.67) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL4069902 0.81 LMNA (0.79) KMT2AMEN1ALDH1A1GAAGFER
SCHEMBL3398708 0.81 KDM1A (0.67) KMT2AMEN1ALDH1A1GAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KMT2A 1059/4885MEN1 4401/4885ALDH1A1 2948/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KMT2A 2732/4885MEN1 3912/4885ALDH1A1 2458/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KMT2A 2732/4885MEN1 3912/4885ALDH1A1 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.